Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Antidepressant or Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)

Use the filters below to narrow your results.

generic:
None (1) · Agomelatine (1) · Amoxapine (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Imipramine (1) · Isocarboxazid (1) · Levomilnacipran (1) · Maprotiline (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Phenelzine (1) · Protriptyline (1) · Reboxetine (1) · Sertraline (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1)
brand:
None (1) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nuplazid (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (18) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1)
starting dose:
None (18) · 25 mg (1) · 34 mg PO once daily (1)
preparations:
None (18) · 10 mg, 34 mg capsules/tablets (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
None (18) · 200 mg/d (1) · 34 mg/d (1)
routes:
None (17) · Oral (3)
onset:
None (17) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Benefit over weeks of dosing (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)
duration:
None (17) · Chronic daily dosing (1) · Daily dosing (1) · Long (1)
halflife:
None (17) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~57 hours (parent), ~200 h (active metabolite) (1)
bioavailability:
None (17) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not characterized; oral dosing once daily (1) · ~50% (highly variable) (1)
pregnancy:
None (17) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid (1)
legal:
None (17) · Rx-only (1) · Rx-only in US (1) · Rx. FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis (class warning shared with all antipsychotics) (1)

Showing below up to 20 results in range #1 to #20.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"